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A B S T R A C T
Multiple Sclerosis (MS) is the second cause of paraplegia among young adults, after all types of CNS traumatic
lesions. In its most frequent relapsing-remitting form, the severity of the disease course is very heterogeneous,
and its reliable evaluation remains a key issue for clinicians. Myeloid-Derived sSuppressor Cells (MDSCs) are
immature myeloid cells that suppress the inflammatory response, a phenomenon related to the resolution or
recovery of the clinical symptoms associated with experimental autoimmune encephalomyelitis (EAE), the most
common model for MS. Here, we establish the severity index as a new parameter for the clinical assessment in
EAE. It is derived from the relationship between the maximal clinical score and the time elapsed since disease
onset. Moreover, we relate this new index with several histopathological hallmarks in EAE and with the per-
ipheral content of MDSCs. Based on this new parameter, we show that the splenic MDSC content is related to the
evolution of the clinical course of EAE, ranging from mild to severe. Indeed, when the severity index indicates a
severe disease course, EAE mice display more intense lymphocyte infiltration, demyelination and axonal da-
mage. A direct correlation was drawn between the MDSC population in the peripheral immune system, and the
preservation of myelin and axons, which was also correlated with T cell apoptosis within the CNS (being these
cells the main target for MDSC suppression). The data presented clearly indicated that the severity index is a
suitable tool to analyze disease severity in EAE. Moreover, our data suggest a clear relationship between cir-
culating MDSC enrichment and disease outcome, opening new perspectives for the future targeting of this po-
pulation as an indicator of MS severity.
1. Introduction
Multiple Sclerosis (MS) is a chronic, autoimmune and degenerative
disease of the Central Nervous System (CNS), in which a glial cell pa-
thology (especially affecting oligodendrocytes and their precursors) is
associated with demyelination, axonal damage and inflammation. To
date, MS remains incurable and it is becoming the most prevalent
chronic inflammatory CNS disease as it affects around 2.3 million
people worldwide, being the second cause of neurological disability
among young adults after the sum of traumatic CNS lesions (Filippi
et al., 2018). Relapsing-remitting MS (RRMS) is the most frequent form
of the disease, in which an exacerbation of the symptoms (relapses) is
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followed by phases of remission. As a result of this pattern of disease
development, it is thought that molecules or specific cell types that
control immune system activity are involved in MS and an eventual (re)
myelination (Bramow et al., 2010; Gualtierotti et al., 2017; Hagemeier
et al., 2012; Kleist et al., 2016; Meyer et al., 2017; Plemel et al., 2017;
Weissert, 2017). In terms of the cells that regulate both the innate and
adaptive immune response, there is a general consensus regarding the
alterations of the number, activity or resistance of the effector cells
involved in T or B cell immunosuppression (Costantino et al., 2008;
Haas et al., 2005; Habib et al., 2015; Michel et al., 2014; Viglietta et al.,
2004). However, there are no data regarding alterations in the number
or activity of myeloid regulatory cells in MS patients.
There is a strong variability among MS patients in terms of disease
severity and there is no way to foretell how the evolution of disease will
be when it is diagnosed after the clinical debut of symptoms. Indeed,
there is a growing interest in defining the relationship between MS
disease severity, remyelination capacity and the cellular agents in-
volved in its control. The difficult physical accessibility to the CNS
tissue in the temporal window prior to the appearance of lesions, to-
gether with the complexity of the mechanisms underlying disease de-
velopment, has hindered the identification of biomarkers of disease
progression. Both the extent and the efficacy of spontaneous re-
myelination in each patient is extremely variable, and it does not seem
to be associated with the age of onset, sex, disease duration, treatment
or clinical variants (El Behi et al., 2017; Patani et al., 2007). To date,
only magnetic resonance imaging (MRI) allows us to obtain partial
information regarding the extent of demyelination and blood-brain
barrier (BBB) dysfunction, especially in early phases of the disease
(Fournier et al., 2017). The observations made through this technique
aid diagnosis and give an orientation about lesion progression and the
potential efficacy of disease modifying treatments (DMTs; Rovira et al.,
2015; Thompson et al., 2018). As a matter of fact, there is an inverse
correlation between the remyelination index obtained using MRI mar-
kers and the degree of neurological disability (Bodini et al., 2016).
Nevertheless, conventional MRI biomarkers have not proven to be
sufficiently robust to establish correlations at demographic levels, al-
though this is probably due to the inherent heterogeneity of MS (Filippi
et al., 2018). To date, the relationship between immune system activity,
and specifically that of the cells regulating both the innate and adaptive
immune response, and the development of a more or less severe clinical
course has been poorly addressed (Bielekova et al., 2006; de Andres
et al., 2014; Morandi et al., 2008). It is highly plausible that, at least in
part, the lack of clinical data is a consequence of the scarce suitability of
the clinical signs employed for that in the available animal models to
address such a complex question.
Considering that the etiology of MS is still unknown, a proper an-
imal model should include MS pathogenic hallmarks that are invariably
present in patient lesions, i.e. T cell and macrophage inflammatory
infiltrates and demyelination, leading eventually to the progression of
axonal damage and oligodendrocyte dysfunction (Lassmann and Bradl,
2017). At this respect, experimental autoimmune encephalomyelitis
(EAE) has been the most commonly used animal model to study MS to
date. This model largely reflects the autoimmune component of MS as it
is based on the neuroinflammation elicited by myelin-autoreactive
CD4+ T cell infiltration into the CNS, with an ensuing destruction of
myelin and damage to the denuded axons. The clinical evolution
eventually associated with these events involves progressive disability
in a caudo-rostral sense (Gold et al., 2006; Miller and Karpus, 2007).
The disease can be induced in an active manner by injecting myelin
peptides, or passively through the transplantation of autoreactive T
cells that specifically act against myelin antigens (Archie Bouwer et al.,
2015; Gold et al., 2006). Similarly to MS patients, EAE comprises an
intrinsic variability and different degree of efficacy, since the suscept-
ibility and the clinical course depends on the autoantigen, the genetic
background and the strain among other aspects. In despite of but also
thank to this wide range of outcomes, the use of EAE has been useful to
address pivotal questions of the pathogenesis of MS, such as the me-
chanisms of T-cell mediated inflammation, the resulting immune da-
mage, the humoral components taking part and other molecular disease
mechanisms revealed after the use of transgenic and gene knock out
models (Karpus, 2020; Lassmann and Bradl, 2017; Morkholt et al.,
2019). Besides this, EAE represents a key tool for MS therapy discovery,
being the preferred model used for the preclinical evaluation of most of
the currently prescribed disease modifying treatments in clinics, as well
as future pro-remyelinating treatments, including anti-NOGO-A and
clemastine as the most promising ones (Bove and Green, 2017; de
Castro and Josa-Prado, 2019; Ineichen et al., 2017; Martin et al., 2016;
Mei et al., 2016). Advances in diagnosis have also been reached after
preclinic evaluation in the EAE model, such as visual evoked potentials
or MRI (Castoldi et al., 2020; Fournier et al., 2017). Classically, disease
severity in EAE has been reported based on clinical aspects of the dis-
ease course, such as the maximal clinical score, the accumulated clin-
ical score, the time of onset or even the associated weight loss (Brochet
et al., 2006; Hasselmann et al., 2017). However, the severity of EAE
symptoms has not been yet explored in a way including the main as-
pects analyzed in the routine clinical practice for MS, e.g. time elapsed
from onset to reach a certain clinical affectation. Moreover, while there
are data about the morpho-functional distribution of the different
monocyte-derived cells during the EAE clinical course (Moline-
Velazquez et al., 2016), the relationship of the different regulatory
myeloid cells with the severity of the EAE disease course has yet to be
established.
In recent years, Myeloid-Derived Suppressor Cells (MDSCs) have
emerged as a new cell type involved in the innate immune response,
exerting a relevant influence over effector T cells in the context of MS.
MDSCs are a mixture of immature myeloid cells that can be split into
two subsets depending on their morphology, immunophenotype and
other biochemical markers (Bronte et al., 2016). Thus, monocytic-
MDSCs (M-MDSCs) are considered to be CD11b+CD33+HLA-DR-/
lowCD14+CD15 whereas polymorphonuclear MDSCs (PMN-MDSCs) are
characterized as CD11b+CD33+HLA-DR-/lowCD14CD15+LOX1low
(Cantoni et al., 2017; Knier et al., 2018). The importance of both MDSC
subsets in MS remains controversial, with some groups showing a clear
preponderance of PMN-MDSCs (Ioannou et al., 2012; Knier et al., 2018)
or M-MDSCs as the subpopulation exerting the immunosuppressive role
(Cantoni et al., 2017). Moreover, MDSCs were recently studied in the
context of the different clinical presentations of MS, whereby MDSCs
from progressive MS patients had a more compromised suppressor ac-
tivity (Iacobaeus et al., 2017). However, there are no data about the
role of these cells in the control of the immune response in MS neither
how MDSC activity and/or their numbers influence the clinical course
and severity of the disease. MDSCs have been studied in the context of
EAE, whereby M-MDSCs have a CD11b+Ly-6ChighLy-6G-/low phenotype
and PMN-MDSCs are classified as CD11b+Ly-6CintLy-6Ghigh (Haile
et al., 2010; Melero-Jerez et al., 2016; Zhu et al., 2007), and both these
subsets were considered to be relevant for the control of effector T cells
(Ioannou et al., 2012; Zhu et al., 2007). Indeed, we previously observed
an inverse correlation between the number and maturity of M-MDSCs
and the clinical outcome in EAE (Moline-Velazquez et al., 2011; Moline-
Velazquez et al., 2014). Moreover, an increase in the number and ac-
tivity of M-MDSCs parallels the amelioration of the clinical course in
different MS animal models (Alabanza et al., 2013; Mecha et al., 2018;
Melero-Jerez et al., 2019).
Hence, we set out here to analyze the severity of the disease course
in EAE by proposing the Severity Index (SI), a novel paradigm similar to
the progression index (PI) used in MS (Kosa et al., 2016; Weideman
et al., 2017), in which the maximal clinical score is related to the days
that elapse from onset of symptoms to the peak of the disease. More-
over, a correlation analysis was carried out between different biological
variables such as the abundance of MDSCs in the peripheral immune
system (i.e. the spleen) and several clinical signs, including the SI, and
different histopathological parameters that are important for MS and
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EAE like demyelination, axonal damage and the apoptotic T cells within
the infiltrated tissue. The data show how the abundance of MDSCs at
the peak of EAE inversely correlates with the milder disease course
displayed by each mouse in the end of the study, as well as with lower
tissue affectation.
2. Material and methods
2.1. Induction of EAE
Female six-week-old C57/BL6 mice were purchased from Envigo
Laboratories (Envigo, Udine, Italy). Chronic Progressive EAE was in-
duced by subcutaneous immunization with 200 μL of the Myelin
Oligodendrocyte Glycoprotein (MOG35–55) peptide (200 μg: GenScript,
New Jersey, USA) emulsified in complete Freund's adjuvant (CFA)
containing heat inactivated Mycobacterium tuberculosis (4 mg: BD
Biosciences, Franklin Lakes, New Jersey, USA). Immunized mice were
intravenously administered Pertussis toxin (250 ng/mouse: Sigma-
Aldrich, St Louis, MO, USA) through the tail vein on the day of im-
munization and 48 h later. EAE was scored clinically on a daily basis in
a double-blind manner as follows: 0, no detectable signs of EAE; 1,
paralyzed tail; 2, weakness or unilateral partial hind limb paralysis; 3
complete bilateral hind limb paralysis; 4, total paralysis of the forelimbs
and hind limbs; and 5, death.
Following ethical standards and regulations, humane endpoint cri-
teria were applied when an animal reached a clinical score ≥ 4, when a
clinical score ≥ 3 was reached for more than 48 h, or whether signs of
stress or pain were evident for more than 48 h, even if the EAE score
was <3. Stress was considered as the generation of sounds, stereotypic
behavior, lordokyphosis, hair loss or weight loss superior to 2 g/day.
During this study, no animals were considered to present signs of stress
or pain, and none reached a clinical score > 3.5.
All animal manipulations were approved by the institutional ethical
committees (Comité Ético de Experimentación Animal del Hospital
Nacional de Parapléjicos), and all experiments were performed in com-
pliance with the European guidelines for animal research (European
Communities Council Directive 2010/63/EU, 90/219/EEC, Regulation
No. 1946/2003), and with the Spanish National and Regional
Guidelines for Animal Experimentation and the Use of Genetically
Modified Organisms (RD 53/2013 and 178/2004, Ley 32/2007 and 9/
2003, Decreto 320/2010).
2.2. Biological variables analyzed
Along this work, three different biological variables were analyzed:
i) clinical signs, ii) splenic content, and iii) histopathological para-
meters. The clinical signs came from the observational evaluation of the
functional behavior of each mouse during their clinical course previous
to its sacrifice: disease severity, accumulated clinical score and maximal
clinical score. The splenic content was studied by the flow cytometry
analysis of the different myeloid and lymphoid subsets within the
spleens of each EAE mouse after their sacrifice at the peak of their
clinical courses: percentage of MDSCs/myeloid cells, percentage of
MDSCs/total splenocytes, percentage of CD3+ T cells/total splenocytes,
percentage of CD4+ T cells/total splenocytes, and percentage of CD8+
T cells/total splenocytes. Finally, the histopathological parameters were
obtained from the analysis of the selected tissue, the spinal cord in this
case, of EAE mice at the peak of the clinical course of each mouse:
density of apoptotic CD4+ T cells, percentage of apoptotic CD4+ T
cells/total CD4+ T cells, total demyelinated area, percentage of de-
myelinated white matter, and percentage of white matter area showing
axonal damage.
2.3. Flow cytometry analysis of splenic populations
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the peak of their clinical symptoms. The tissue was homogenized to a
single cell suspension, passed through a 40 μm nylon cell strainer (BD
Biosciences) and washed in RPMI medium (Gibco-Thermo Fisher
Scientific, Waltham, MA USA) supplemented with 10% heat-inactivated
Fetal Bovine Serum (FBS: Gibco) and 1% penicillin/streptomycin (P/S:
Gibco). After erythrocyte lysis in ACK lysis buffer (8.29 g/L NH4Cl, 1 g/
L KHCO3, 1 mM EDTA in distilled H2O at pH 7.4: Panreac, Barcelona,
Spain), 2 x 106of the splenocytes were resuspended in 50 μL of staining
buffer (sterile 1× Phsphate Buffered Saline- PBS- supplemented with
10% FBS, 25 mM HEPES buffer and 2% P/S: Gibco) and their Fc re-
ceptors were blocked for 10 min at 4 °C with anti-CD16/CD32 anti-
bodies (10 μg/mL: BD Biosciences). After blocking, the cells were la-
beled for 30 min at 4 °C in the dark with 50 μL of the corresponding
antibody panel in staining buffer (Table 1): a Pacific Blue conjugated
hamster anti-mouse CD3; a FITC conjugated rat anti-mouse Ly-6C; a R-
PE conjugated rat anti-mouse Ly-6G; a PErCP-Cy5.5 conjugated rat anti-
mouse CD11b (all from BD Biosciences); an APC conjugated mouse anti-
mouse CD11c; and an e-Fluor-450 conjugated mouse anti-mouse F4/80
(eBioscience-Thermo Fisher Scientific). The splenocytes were then
washed twice with staining buffer, recovered by centrifugation at
1500 rpm for 5 min at room temperature (RT), resuspended in PBS and
finally analyzed in a FACS Canto II cytometer (BD Biosciences) at the
Flow Cytometry Service of the Hospital Nacional de Parapléjicos. Both
the percentages and the mean fluorescence intensity (MFI) of the cells
were assessed using the FlowJo 7.6.4 software (Tree Star Inc., Asha-
land, OR, USA).
2.4. Tissue extraction and eriochrome cyanine for myelin staining
After removing their spleen, all the animals were perfused trans-
cardially with 4% paraformaldehyde (PFA: Sigma-Aldrich) in 0.1 M
Phosphate Buffer, pH 7.4 (PB), and their spinal cords were dissected out
and post-fixed for 4 h at RT in the same fixative. After immersion in
30% (w/v) sucrose in PB for 12 h, coronal cryostat sections (20 μm
thick: Leica, Nussloch) were thaw-mounted on Superfrost® Plus slides.
A randomly selected sub-cohort of 12 EAE mice belonging to the main
cohort previously used for the spleen analysis were studied histologi-
cally.
To visualize myelin, eriochrome cyanine (EC) staining was carried
out as described previously (Moline-Velazquez et al., 2011). Briefly, the
sections were air-dried for 2 h at RT and 2 h at 37 °C in a slide warmer.
The sections were then placed in fresh acetone for 5 min and air-dried
for 30 min before they were stained in 0.5% EC for 30 min and dif-
ferentiated in 5% iron alum and borax-ferricyanide for 15 and 20 min,
respectively (briefly rinsing the sections in tap water between the
steps). After washing with abundant water, correct differentiation was
assessed under the microscope whereby the myelinated areas were
stained in blue and demyelinated areas appeared white-yellowish. The
stained sections were dehydrated and mounted for preservation at RT.
2.5. Immunohistochemistry and apoptosis
After several rinses with PB, the sections from EAE mice in the
histological sub-cohort were pre-treated for 15 min with 10% methanol
in PB and they were pre-incubated for 1 h at RT in incubation buffer:
5% normal donkey serum and 0.2% Triton X-100 (both from Merck)
diluted in PBS. Immunohistochemistry was performed by incubating
the sections overnight at 4 °C with the primary antibodies diluted in
incubation buffer: SMI-32 (1:200, Covance, Princeton, NY, USA), CD4
(1:25, eBioscience, San Diego, CA, USA). After rinsing, the sections
were then incubated for 1 h at RT with the corresponding fluorescent
secondary antibodies in incubation buffer (1:1000, Invitrogen, Paisley,
UK). Apoptosis was assayed by TUNEL using the ApoTag® Plus
Fluorescein in situ Apoptosis Detection Kit (Millipore, Billerica, MA,
USA) according to the manufacturer's instructions. In all cases, the cell
nuclei were stained with Hoechst 33342 (10 μg/mL, Sigma-Aldrich)
and the sections were mounted with coverslips in Fluoromount-G
(Southern Biotech, Birmingham, AL, USA).
2.6. Image acquisition and analysis
In all cases, 3 sections from each thoracic spinal cord (with a se-
paration of 420 μm) were selected from the 12 EAE mice in the histo-
logical sub-cohort. To measure demyelination, the EC stained spinal
cord sections were analyzed on a stereological Olympus BX61 micro-
scope, using a DP71 camera (Olympus) and VisionPharm software for
anatomical mapping. Superimages were acquired at a magnification of
10× using the mosaic tool and analyzed with Image J, expressing the
results as the percentage of white matter area with no signs of blue
staining.
To quantify axon damage, mosaic images from the whole spinal
cord of each animal were obtained on a DMI6000B microscope (Leica).
The area of axon damage relative to the total area or the demyelinated
area was analyzed with an ad-hoc plug-in designed by the Microscopy
and Image Analysis Service of the Hospital Nacional de Parapléjicos.
Briefly, after selecting the appropriate area (the lesioned area relative
to the whole section area or to the whole white matter area), a
threshold for immunofluorescence was assessed and the SMI-32 im-
munostaining was measured, representing the result in μm2.
For the CD4/TUNEL analysis, the total number of cells within the
infiltrated CNS tissue was assessed on a Leica confocal microscope using
the Suite 2.7.0R1 application, manually counting the cells. Twelve
images from different levels of each demyelinated area were assessed to
avoid counting cells more than once (z-stack at 1 μm intervals, 40×).
The density of the stained cells was considered in terms of the in-
filtrated area (measured with the Image J software).
2.7. Statistical analysis
The data are expressed as the mean ± SEM and they were analyzed
with SigmaPlot version 11.0 (Systat Software, San Jose, CA, USA). A
Student's t-test for parametric distributions or a Mann-Whitney U test
for non-parametric distributions were used to compare pairs of the
different groups of mice. A Spearman test was carried out for the cor-
relation analyses. Minimal statistical significance was set at p < 0..05: *
p < 0.05; ** p <0.01; ***p <0.001.
3. Results
3.1. Classification of the clinical course of EAE and clinical sign description
Animals were evaluated daily from the day of immunization until
the day they were sacrificed, taking note of their clinical score, and
establishing the following clinical signs: disease onset (the first day with
a clinical score between 0.5 and 1.5 and with an increased clinical score
the following day); maximal score (“peak” is defined as the first day a
clinical score ≥ 2 was observed as a repeated score or the day before
clinical recovery); disease duration at peak (days elapsed from onset to
peak); and accumulated score at peak (the sum of all the clinical scores
from disease onset to the peak).
As in MS, there is variability in the outcome of EAE in terms of all
these signs. Indeed, some of the animals showed a rapid disease pro-
gression, reaching an elevated maximal score within a few days and
losing a large percentage of their body weight, while in other animals
the phase in which the symptoms deteriorated lasted longer, they
achieved a lower maximal score over a more prolonged time period,
and possibly with less weight loss (Fig. 1A-B; Table 2). To take this
variability into account, we established the so-called SI, similar to the PI
used in clinical practice (Kosa et al., 2016; Manouchehrinia et al., 2017;
Weideman et al., 2017). The SI was calculated as the ratio between the
maximal score at peak and the disease duration, according to the for-
mula:
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Severity index (SI)
Maximal clinical score (peak)/days elapsed from onset to peak=
In our cohort of 20 mice, the SI ranged from 0.30–1.17, with a
mean ± SEM of 0.59 ± 0.05 and a median of 0.55 (Interquartile range
–IQR = 0.44–0.75).
We were interested in the existence of the relationship between the
clinical signs and the immunological composition of their peripheral
immune organs. To this end, we performed several correlation analyses
between the clinical signs and the splenic content of each animal. To
check whether the abundance of MDSCs in the spleen at the peak of the
disease was related to a more or less severe clinical course of EAE
(Fig. 1C-D), a correlation analysis of the abundance of MDSCs in the
spleen and the different clinical signs was carried out (Fig. 2). The
proportion of MDSCs relative to both the myeloid component and the
total splenic content was not significantly correlated to the maximal or
accumulated clinical score (Fig. 2A-D). Interestingly, a very significant
inverse correlation was observed between the abundance of MDSCs and
the SI of each animal (Fig. 2E-F). These results suggest MDSCs were
related with the severity of the EAE clinical course previously followed
by each animal.
3.2. The splenic abundance of MDSC is related to the presence of a less
prominent lymphoid subset and a milder disease course
MDSCs are cells of the innate immune system that regulate T cell
activity in EAE (Melero-Jerez et al., 2019), although it is not clear if the
abundance of peripheral T cells is a marker of a previous more severe
disease activity in this model. An analysis of the splenic lymphoid
component (percentage of CD3+, CD4+ and CD8+ cells/total spleno-
cytes) of EAE mice at the peak of the disease course showed a direct and
significant correlation between their abundance and the previous dis-
ease severity (Fig. 3A-C). By contrast, and as for MDSCs, CD3+, CD4+
and CD8+ T cell content in the spleen was not significantly correlated
with either the maximal or accumulated clinical score showed by each
mouse at the time of sacrifice, except when considering the case of CD8
T cells and the maximal clinical score: CD8+ vs. maximal score,
r = 0.489, p = 0.028.
Since the SI is the most prominent clinical sign that was correlated
to both MDSC and T cell abundance, we subdivided the EAE mice
(n = 20) into two groups, those with a SI lower than or higher than the
median of the cohort (for the clinical parameters of these two sub-
groups see Table 3). The values for all the analyzed clinical signs dif-
fered significantly between both sub-groups, except the accumulated
clinical score. Indeed, EAE mice with a SI lower than the median (i.e.
mild EAE mice) also presented a lower maximal score, and a longer
disease duration from onset to peak (Table 3). The splenic content
comparison of the different T cell subsets and MDSCs between both sub-
cohorts indicated that although there was an increase in the percentage
of CD3+, CD4+ and CD8+ T cells with respect to the total splenocytes
in EAE mice that had developed a severe disease, it did not reach sta-
tistical significance (Fig. 4A). By contrast, a comparison of the
Fig. 1. The MDSC population is less prominent in animals with a more severe EAE clinical course. A-D: Representative examples of the clinical course/weight loss
(A,B) and the flow cytometry analysis of the population of splenic MDSCs (C, D) in a mouse with a SI above (SI = 0.875; A, C) and below (SI = 0.5; B, D) the median
of the group of animals studied.
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percentage of splenic MDSCs with respect to the total splenocytes re-
flected a highly significant decrease in this regulatory cell subset in
those EAE mice that had experimented a more severe disease progres-
sion (Fig. 4A). The same statistical difference was observed after com-
paring the splenic MDSCs relative to the myeloid subset (not shown;
p <0.001). In this sense, the splenic content of CD3+, CD4+ or CD8+
cells within the whole splenocyte populations reflected a significant
inverse correlation with the abundance of MDSCs within the myeloid
subset (Fig. 4B, D, F) or, even clearer, within the total splenocyte po-
pulation (Fig. 4C,E,G).
All these correlations clearly indicated a differential frequency in
splenic MDSC content depending on the EAE clinical evolution followed
by the animals, with a higher percentage in mice that had suffered a
milder disease course and related to a less prominent lymphoid content.
3.3. The SI and the peripheral MDSC load are related to T cell apoptosis in
the CNS
We explored the correlation between the SI and the abundance of
MDSCs in the spleen and different histopathological parameters of EAE,
such as T cell viability (i.e. density and percentage of apoptotic T cells),
demyelination and axonal damage. We randomly selected 12 of the 20
mice from the earlier clinical and splenic analysis, a new histopathology
sub-cohort with their own clinical sign values (Table 4). The median SI
of this new sub-cohort was 0.613, slightly higher than that of the total
cohort of 20 mice (Table 2). We assessed whether there was a similar
correlation between the splenic MDSC content and the different clinical
signs. As in the case of the total cohort of 20 mice, the abundance of
splenic MDSCs with respect to the myeloid subset or to the total number
of splenocytes was only inversely but moderately correlated with the SI
(all the statistics are collected in Sup. Table 1).
Fig. 2. The percentage of splenic MDSCs is indicative of a less severe clinical evolution. A-D: The maximal (A, B) and the accumulated clinical score (C, D) was not
correlated with either the amount of MDSCs relative to the myeloid component (A, C) or the total splenocytes (B, D). E-F: The abundance of splenic MDSCs relative to
the myeloid component (E) or the whole splenocyte content (F) was inversely correlated with the severity of the disease course (n = 20 mice). The statistical analysis
were carried out using a non-parametric Spearman correlation coefficient.
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The main mechanism underlying MDSC immunosuppression is the
blockade of self-reactive CD4+ and CD8+ T cell proliferation, and the
promotion of their anergy/apoptosis (Mecha et al., 2018; Melero-Jerez
et al., 2016; Moline-Velazquez et al., 2011; Moline-Velazquez et al.,
2014; Zhu et al., 2011). We checked whether the correlations between
the splenic MDSCs and T cells persisted in the group of animals in which
we did the histopathological analysis. Almost all the correlations ob-
served between the splenic MDSC content and the splenic lymphoid
cells in the global cohort of EAE mice were detected in the histo-
pathological subgroup of 12 EAE mice (Sup. Table 2). Indeed, the ob-
served correlations between these parameters were stronger than in the
case of the SI, especially when MDSCs and T cells were both related to
the total splenocytes (Sup. Table 2).
As the peripheral T cell content is inversely related to the previous
clinical course severity, we also studied the presence and viability of
CNS infiltrated T cells in mice with different SI. The apoptosis of CD4+
T cells was assessed using a TUNEL assay, demonstrating that EAE mice
that had suffered from mild EAE tended to have higher, yet not sig-
nificant, density of apoptotic T cells than severe EAE mice, or the
proportion they represented within the whole CD4+ T cell population
in the inflammatory infiltrates of the EAE spinal cord was higher at the
peak of the disease (Fig. 5A-H). As in the previous cases, the statistical
analysis showed that, in the spinal cord, both the density and the per-
centage of apoptotic CD4+ T cells within the whole CD4+ T cell po-
pulation did not correlate with either the maximal or accumulated
clinical score of each mouse at the time of sacrifice (Sup. Table 3).
Remarkably, the SI at the end of the experiment showed a moderate
inverse correlation with the density of apoptotic CD4+ T cells within
the spinal cord of each EAE mouse but not with the percentage they
represented within the whole CD4+ T cells distributed in the infiltrated
white matter (Fig. 5I-J). Moreover, the higher abundance of splenic
MDSCs was significantly related to both the higher density and the
proportion of apoptotic CD4+ T cells within the inflamed spinal cord
(Fig. 5K-N). These data reinforced the following ideas: i) although the SI
just shows a moderate signification in the statistical analysis, it seems to
be the best parameter to monitor the viability of CD4 T cells and ii) the
peripheral splenic MDSC content is related to the viability of T cells in
the spinal cord of EAE mice at the peak of the disease.
3.4. The SI and the peripheral abundance of MDSCs associate with less
myelin destruction and axonal damage
As in the case of MS, demyelination and axonal damage are two of
the main histopathological hallmarks of EAE spinal cord affectation. At
the peak of the clinical course, the spinal cord of EAE mice showed
different areas of myelin destruction that were more prominent in those
animals which suffered a severe disease course (Fig. 6A-B), being sig-
nificantly less pronounced in mild than in severe EAE mice (Fig. 6C-D).
Although the extent of myelin destruction showed a significant but
moderate inverse correlation (p <0.05) with the maximal clinical score
(but not with the accumulated clinical score; Sup. Table 3), it was
statistically much more intense when it took into account the SI
(p <0.000001; Sup. Table 3; Fig. 6E-F). Interestingly, both the pro-
portion of splenic MDSCs with respect to the myeloid subset and with
respect to the total splenocytes at the time of sacrifice were inversely
correlated to the whole area of affected myelin (Fig. 6G-H), as well as
with the degree of myelin destruction within the spinal cord white
matter of each animal (Fig. 6I-J).
Axonal damage is a direct consequence of the extent of total and/or
sustained demyelination (Dandekar et al., 2001; Haines et al., 2011).
The axonal damage in the spinal cord of EAE mice with different clin-
ical evolutions was studied, as was its relation to the splenic MDSC
content at the time of sacrifice. This was achieved using a specific
marker for the non-phosphorylated form of the neurofilament protein,
NFH (SMI-32), as reported previously (O'Sullivan et al., 2017; Wegner
et al., 2006). Like for the previous histopathological analysis, axonal
damage in the spinal cord was clearly prominent in those mice with a SI
higher than the median (i.e. severe EAE mice), both within the in-
flammatory lesion and in the deep white matter (Fig. 7A-F). Indeed,
EAE mice with a higher SI displayed significantly more damage on
axons than mild EAE mice (Fig. 7E). Like apoptotic T cells, axonal da-
mage did not correlate with the maximal or accumulated clinical score
(Sup. Table 3). In contrast, axonal damage moderately correlated with
the SI (p <0.05). Moreover, and like the degree of demyelination, the
peripheral MDSC contribution to the myeloid subset or to the whole
splenic population was significantly related to the degree of axonal
damage in the spinal cord of EAE mice at the peak of the disease course
(Fig. 7H).
In conclusion, the severity of the EAE clinical course assessed using
the SI measured at the peak of the EAE clinical course was the only
clinical sign indicative of both more widespread myelin destruction and
Fig. 3. The size of the splenic T cell population is directly related to EAE se-
verity. A-C: Correlation plots showing a direct relationship between the Severity
Index with the different T cell subsets (CD3+ cells A; CD4+ cells B; CD8+ cells
C: n = 20 mice). The statistical analysis was carried out using the non-para-
metric Spearman correlation coefficient.
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Fig. 4. The splenic MDSC population is less abundant in mice with a severe EAE clinical course and it is inversely related to the proportion of T cells. A: The MDSC
content in the myeloid splenic component was higher in EAE mice suffering from a mild disease course than in those with more severe EAE. The T cell content was
similar in both groups of animals. B-G: Correlation analysis of the inverse and significant covariation between the number of splenic T cells and the splenic content of
MDSCs (relative to the myeloid component B, D, F; relative to the total number of splenocytes C, E, G: n = 20 mice). In A, the result of a Student's t-test between the
mild versus severe EAE mice is shown where **p <0.01. The correlation analysis were carried out using the non-parametric Spearman correlation coefficient.
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more intense axonal damage in the spinal cord of EAE mice, which was
extremely prominent in the case of the extent of demyelination. Both
these classical histopathological parameters were inversely related to
the presence of splenic MDSCs at the same time point.
4. Discussion
In spite of its several and important differences with the human
disease, EAE is still the most used animal model for MS with a wide-
spread use in successful preclinical assays (Lassmann and Bradl, 2017;
Moliné-Velázquez et al., 2016; Moreno et al., 2012). Our present study
shows that the EAE animal model presents important inter-individual
variability in terms of the classical clinical signs defining the disease
course, such as the maximal clinical score, days from immunization to
disease onset, and the accumulated score. However, most of them are
irrelevant for their comparative analysis with MS clinical practice. For
this reason, it is important to find new tools for EAE evaluation that can
be useful to parallel the animal model to the real human disease, e.g. a
high variability in terms of disease severity, and thus increase the re-
liability of the results obtained from the model. Interestingly, our data
show that not all the EAE mice reach a similar maximal affectation at
the same velocity, i.e. the SI of the disease course, which we propose in
our present work. Far from being an obstacle, the existence of this
variability in the severity of the disease course moves this model closer
to the real scenario of MS and it even strengthens more the suitability of
EAE as a proper tool for MS preclinical studies. Moreover, our data
clearly indicate that the SI is so far the best clinical sign to proper es-
tablish robust relationships with the peripheral splenic immune system
composition, i.e. lymphocyte and myeloid content, and with the extent
of tissue damage affectation in terms of lymphocyte apoptosis, de-
myelination and axonal damage. However, it is clear after our present
study that the SI shows a heterogeneous relationship with the different
analyzed variable in EAE: i) the SI is the only clinical sign that corre-
lates with the splenic MDSC abundance; ii) the SI is the only clinical
sign that correlates with all the measured histopathological parameters,
among which demyelination shows the highest statistical significance.
The first aspect seems to indicate that the SI should be included among
the clinical signs to take into account to evaluate EAE severity. The
second aspect clearly shows that the extent of myelin destruction might
be the most important event in EAE, just immediately behind the se-
verity of the clinical course. These observations agree with previous
ones in MS showing that the number of demyelinated foci in the spinal
cord of MS patients (measured as super intense MRI abnormalities) is
related to a higher severity of their clinical courses (Nijeholt et al.,
2001). Moreover, it has also been shown in MS spinal cord tissue that
axonal damage extent is not related to both plaque load and disease
duration (DeLuca et al., 2006). At this respect, it is important to define
universal criteria of “disease severity”, together with standard tools for
its measurement, both in the human and animal disease. To date, dif-
ferent scales have been developed to measure patient evolution, the
Expanded Disability Status Scale (EDSS) being that most often used
(Kalincik et al., 2017; Lapucci et al., 2019). The introduction of the
factor “disease duration” in the PI or the Multiple Sclerosis Severity
Score (MSSS) represented an important improvement, extended its
clinical use and facilitating better choices in DMT selection (Roxburgh
et al., 2005). However, the complexity in diagnosing MS is accentuated
by the additional difficulty in defining the exact moment of disease
onset (generally assigned in a retrospective analysis) and thus, disease
duration. Here we took advantage of the standard EAE model in which
the precise clinical onset can be determined by the immediate reflex in
clinical signs. This fact permitted us to define a new parameter, the SI,
that resembles the clinical PI and that also displays a degree of inter-
individual variability. Although in daily clinical practice the MSSS is
considered a more powerful index for cross-sectional analysis
(Roxburgh et al., 2005), it cannot be adapted to EAE, while the PI re-
mains a useful tool to evaluate the severity of the MS disease progres-
sion (Javor et al., 2018). Other scales have appeared in recent years
that normalize the EDSS, taking into account the age of the patient at
the moment of evaluation (ARMSS) or the weight loss (CombiWISE:
(Kosa et al., 2016; Manouchehrinia et al., 2017). When applied to EAE,
the first lacks relevance as all mice are the same age, while the second
parameter seems to be used as an important factor to define disease
severity.
An earlier multiparametric analysis using a global cohort led to the
conclusion that the most influential factors in MS disease progression
are age, disease duration, type of clinical course, previous relapse ac-
tivity, degree of disability, predominant phenotype during the relapse
and prior therapy (Kalincik et al., 2017). The clinical evolution of MS is
quite varied, grouped by clinical parameters in the RRMS and pro-
gressive variants (with more or less MRI activity), yet it is as hetero-
geneous as the patient population. Hence, to better diagnose and choose
an adequate therapy, it is necessary to better understand the factors
that determine the clinical evolution of each patient once the disease
has commenced. The standardization of an animal model like EAE,
given the homogeneity of the individuals in terms of age, gender and
animal housing, may reduce the confounding factors that may generate
variability in the sample. Nevertheless, variability may also be pro-
voked by hormonal changes, such as the point of the estrus cycle (Lelu
et al., 2011; McClain et al., 2007; Offner and Polanczyk, 2006), or the
microbiota (Colpitts et al., 2017; Wilck et al., 2017), parameters in-
trinsic to the individual. Here the splenic myeloid component was seen
to be enriched in MDSCs as EAE progressed, although further studies
will be necessary to determine whether this is a cause or a consequence
of this variability, and whether this parameter at onset serves as an
indicator of damage at the CNS level.
We found that the splenic MDSC content at the time of animal sa-
crifice is inversely related to the previous experimented severity of the
clinical course and the histopathological parameters of the injured CNS,
such as reduced demyelination and axonal damage. Although inter-
esting enough, to consider MDSCs as a good immunological parameter
in MS to predict the future disease severity and to monitor the extent of
tissue damage, needs from further intense research. In terms of the
myeloid population in EAE, macrophages dominate the inflammatory
infiltrates within the CNS and their numbers were correlated to EAE
severity (Ajami et al., 2011; Huitinga et al., 1993; Huitinga et al.,
1990). Indeed, a higher EAE severity (measured as the increase in the
maximal score) was related to the infiltration of monocytes with a
CD45hiCD11b+Ly-6G-Ly-6C+CD11c+MHC-II+ phenotype, as well as
the presence of more MHC-II-expressing microglia (De Feo et al., 2017).
Moreover, EAE severity has been related to the number of monocytes in
the spinal cord, and mice in which monocytes are deficient in CCR2 are
protected against EAE due to their inability to colonize the CNS (Ajami
et al., 2011; Fife et al., 2000; Mildner et al., 2009). Based on this in-
formation, CD11b+Ly-6G-/lowLy-6Chigh cells (Ly-6Chigh cells) have
generally been considered highly pro-inflammatory cells. However, Ly-
6Chigh cells behave distinctly depending on the point in the clinical
course when they are isolated. As such, they are pro-inflammatory at
the onset of the disease whereas they show a powerful im-
munosuppressive role when isolated at the peak of the clinical course
(Moline-Velazquez et al., 2011; Zhu et al., 2011). It was recently re-
ported that 50% of the CNS infiltrated ArgeI+ anti-inflammatory
Table 2
Main clinical parameters of the whole cohort of EAE mice at the peak of the
clinical course (n = 20 mice).
Clinical parameter Range Mean SEM Median IQR
Maximal score 1.5–3.5 2.77 0.10 3.0 2.5–3.0
Accumulated score 5.5–14.0 10.27 0.50 10.0 8.5–12.0
Disease duration (days) 3–7 5.00 0.24 5.00 4–6
Severity Index 0.30–1.17 0.59 0.05 0.55 0.44–0.75
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Fig. 5. There is more CD4+ T cell apoptosis in the spinal
cord of mice with more MDSCs in the spleen. A-F:
Representative images of a spinal cord lesion in a mouse
with a SI below (A-C) and above (D-F) the median. CD4+ T
cells are shown in red, apoptotic cells in green (TUNEL+
cells), the yellow arrows point to the double positive cells
and the asterisks to viable CD4+ T cells. G-H: The density
and percentage of apoptotic CD4+ T cells tended to be
differet in the spinal cord of mice that had experimented a
severe or mild EAE disease course. I-J: The density of CD4+
T cells but not the proportion of the whole CD4 T cell po-
pulation they represent was correlated with the SI. K-N:
Correlation plots showing a direct and significant relation-
ship between the density (K, M) and percentage (L, N) of
apoptotic CD4+ T cells and the number of splenic MDSCs,
with respect to both the myeloid component (K, L) and the
total of splenocytes (M, N: n = 12 mice). Scale bar: A-
F = 10 μm. The Student's t-test was used to compare the
groups and a Spearman correlation coefficient was used for
the correlation analysis. (For interpretation of the refer-
ences to colour in this figure legend, the reader is referred
to the web version of this article.)
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macrophages obtained at the peak of the clinical course were derived
from iNOS+ pro-inflammatory cells invading the CNS at the onset of the
disease (Giles et al., 2018). Moreover, transplantation of immature
myeloid cells at the onset of EAE delayed the appearance of symptoms
and their severity (Zhu et al., 2011), as occurs with the transplantation
of PMN-MDSCs (Ioannou et al., 2012). Therefore, there is no doubt that
Ly-6Chigh cells at the peak of the disease have a phenotype and activity
similar to MDSCs. Indeed, we proved that fewer and less differentiated
MDSCs at the peak of the EAE were associated with a worse clinical
course (Moline-Velazquez et al., 2014). Notably, the pharmacological
induction of an increase in MDSCs in both the spleen and CNS com-
partments is always accompanied by the amelioration of the disease
course, not only in EAE, but also in other demyelinating animal models
(Alabanza et al., 2013; Mecha et al., 2018; Melero-Jerez et al., 2019).
Together with our current observations, these data clearly indicate that
a high percentage of Ly-6Chigh MDSCs at the peak of disease activity is
related to a previous milder disease course. Moreover, in all these cases,
the modification on the enrichment of splenic MDSC parallels an in-
verse variation in the abundance of splenic T cells both at the peripheral
immune organs and within the CNS parenchyme. In our present study,
the relationship between MDSCs and T cell abundance is even more
evident when MDSCs are related to the whole splenic content than to
the myeloid subset. This suggests that comparing the cell carrying out
the activity (the MDSCs) with the target cell (the T cells) within the
same cell compartment should be, statistically and immunologically, a
better approach for future studies.
Evidence for the participation of Th1 and Th17 cells in the patho-
physiology of MS and EAE severity has come from both genetic
(International Multiple Sclerosis Genetics et al., 2011) and in vivo
studies, whereby alterations in the presence or activity of these cells
modifies the onset and progression of EAE (Becher et al., 2002;
Hofstetter et al., 2005; Komiyama et al., 2006) and MS (Brucklacher-
Waldert et al., 2009; Durelli et al., 2009a; Durelli et al., 2009b). The
activation of mast cells was seen to be one of the triggering events in
EAE (Christy et al., 2013), together with the meningeal inflammation
and neutrophil infiltration (Ajami et al., 2011; Christy et al., 2013; Wu
et al., 2009), all contributing to the tissue destruction in the acute phase
of EAE. A few studies have explored the correlations between these cells
in the blood and the severity of the clinical course in each patient. The
relationship between MS and various subfamilies of the TCR subunits in
lymphocytes has been studied (Laplaud et al., 2006; Montes et al.,
2009; Prat et al., 2005). For monocytes, MS patients have a prevalent
CD16 rather than a CD14 phenotype (Gjelstrup et al., 2018; Nakajima
et al., 2004), yet it is not known whether their presence, phenotype or
activity is related to the severity of MS. The ratio of the different cell
types or activity states has been studied in recent years to assess the
relationship between MS course and the peripheral immune system
component. In this sense, the ratio between effector cells and Treg or
lymphocytes/monocytes has been used in attempts to search for bio-
markers of conversion from Clinically Isolated Syndrome (CIS) to MS,
or for rapid disease progression (Nemecek et al., 2016; Waid et al.,
2014). Surprisingly, while the diminished suppressive capacity of Treg
and Breg populations has for years been known to be a cause of disease
progression (Costantino et al., 2008; Haas et al., 2005; Habib et al.,
2015; Michel et al., 2014; Viglietta et al., 2004), they have barely been
studied in terms of their potential as biomarkers of progression (de
Andres et al., 2014), with the regulatory CD56bright NK cells the best
studied (Bielekova et al., 2006; Morandi et al., 2008). However, little or
nothing is known about the relationship between regulatory cell po-
pulations of the myeloid lineage and the severity of MS disease pro-
gression.
In the case of MDSCs, further research is needed to determine the
exact MDSC phenotype in humans and how these cells control the im-
mune response in MS. To date, the participation of the different MDSC
subsets in MS remains controversial. The first study into MDSCs in MS
focused on PMN-MDSCs as the preponderant subset in RRMS patients
during relapse, with little or no participation of M-MDSCs (Ioannou
et al., 2012). However, M-MDSCs were shown to be the only subset that
decreased in RRMS during relapse (Cantoni et al., 2017). When com-
paring MDSCs from RRMS and SPMS patients, a reduction in both M-
MDSCs and PMN-MDSCs was described in SPMS. Moreover, M-MDSCs
from SPMS promoted autologous T-cell proliferation in contrast to the
traditional suppressive function of M-MDSCs from healthy controls or
RRMS patients (Iacobaeus et al., 2017). A very recent analysis of PMN-
MDSCs in RRMS patients at baseline and after a follow up period
identified a reduction in the number of these regulatory cells during
relapse, and an increase in MS subjects close or entirely within NEDA-3
(i.e. no evidence of disease activity: Knier et al., 2018). Such data are
consistent with that presented here in EAE, where a previous milder
disease severity is paralleled by a higher abundance of peripheral
MDSCs.
Here we correlated the abundance of peripheral splenic MDSCs at
the peak of EAE with CNS histopathology. It is beyond the scope of this
work to establish a causative relationship between the amount of per-
ipheral M-MDSCs and the degree of demyelination, axon damage or
apoptosis of lymphocytes within the CNS. The abundance of both
splenic and CNS MDSCs at the peak parallels the clinical course of EAE,
increasing as the symptoms progress and gradually decreasing with
clinical recovery (Moline-Velazquez et al., 2011; Zhu et al., 2007).
However, there is a 4 day delay in the time course of their abundance in
the CNS relative to the periphery. Hence, MDSCs not only exert im-
munosuppression in the periphery but also in the CNS parenchyma,
which may imply that both compartments communicate continuously
during the effector phase of EAE to maintain homeostasis. As such,
Table 3
Main clinical parameters of the whole cohort of EAE mice at the peak of the clinical course divided by the median of the severity score (n = 10 for mild or severe EAE
mice).
Clinical parameter Disease severity Range Mean SEM Median IQR Statistics
Maximal score < median 1.5–3.0 2.54 0.15 2.5 2.25–3.0 p < 0.05
> median 2.5–3.5 3.0 0.11 3.0 3.0–3.0
Accumulated score < median 5.50–14.00 10.78 0.80 11.25 10.00–12.75 p =0.323
> median 7.50–13.00 9.76 0.59 9.25 8.50–11.50
Disease duration (days) < median 5–7 5.80 0.25 6.0 5–6 p < 0.001
> median 3–5 4.20 0.20 4.0 4–5
Severity Index < median 0.30–0.50 0.44 0.02 0.44 0.41–0.50 p <0.001
> median 0.60–1.17 0.75 0.06 0.75 0.60–0.75
Table 4
Main clinical parameters of the sub-cohort of EAE mice used for the histological
analysis at the peak of the clinical course (n = 12).
Clinicalparameter Range Mean SEM Median IQR
Maximal score 1.5–3.5 2.81 0.16 3.0 2.5–3.0
Accumulated score 5.5–13.0 9.80 0.70 9.5 8.0–12.0
Disease duration (days) 3–7 4.58 0.29 4.5 4–5
Severity Index 0.30–1.17 0.60 0.05 0.613 0.44–0.75
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Fig. 6. The abundance of splenic MDSCs is indicative
of weaker demyelination in the spinal cord of EAE
mice. A-B: Spinal cord section stained for eriochrome
cyanine from a mouse with a mild (A) and severe (B)
disease course. The demyelinated areas are defined
by a black dashed line. C-D: EAE mice that experi-
enced a severe clinical course had larger demyeli-
nated areas, both in terms of the absolute number (C)
and the proportion of the white matter affected (D).
E-F: There was a significant correlation between both
measurements and the SI. G-J: The percentage of
splenic MDSCs, both relative to the myeloid compo-
nent (G, I) and to the total splenocytes (H, J), was
inversely correlated with both the demyelinated area
(G, H) and the proportion of the whole spinal cord
white matter it represented (I, J: n = 12 mice). Scale
bar: A-B = 200 μm. The Student's t-test was used to
compare the groups and a Spearman coefficient for
the correlation analysis.
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Fig. 7. The spinal cord of mice with a more severe EAE had more axonal damage, directly related to the splenic MDSC content. A-D: Detailed views of transverse
sections of the spinal cord of a mouse with a mild (A-B) and severe (C-D) disease course, showing the lesioned area (A, C) or the deep white matter (B, D). Sections
were stained for SMI-32 (in green) and the nuclei with Hoechst (blue), the white arrows indicating SMI-32 positive axons. The lesion area is defined by the dashed
orange line, while the white dashed line separates the grey (GM) from the white matter (WM) E: The proportion of axonal damage in the WM is much higher in the
animals with more severe EAE than in those with mild EAE. F: Correlation plot showing that the extent of axonal affectation is related to a more severe disease course.
G-H: The abundance of MDSCs, both relative to the myeloid component and the total splenocytes is inversely correlated with milder axonal affectation in the WM of
the spinal cord of EAE mice (n = 12 mice). Scale bar: A-B = 25 μm. A Student's t-test was used to compare the groups and the Spearman coefficient for the correlation
analysis. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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more MDSCs in the spleen would lead to a greater infiltration of the
CNS. Indeed, TREM2-transduced bone marrow-derived myeloid cells
transplanted at the peak of EAE selectively colonized the inflammatory
area of the CNS within 2 h of transplantation and they were still present
in the CNS parenchyma even 5 days later, without acquiring a mature
microglial phenotype (Takahashi et al., 2007). As shown in our present
work, macrophage infiltration in the inflammatory lesions of EAE is
correlated with EAE severity, particularly in terms of tissue damage,
inflammation, demyelination and axonal damage (Brochet et al., 2006).
Moreover, TREM2-transduced bone marrow-derived myeloid cells in-
terfere with the disease course when transplanted at the peak of the
clinical course but not at disease onset (Takahashi et al., 2007). Indeed,
there was milder demyelination and axonal damage in transplanted
animals than in control EAE mice. Elsewhere, the presence of mono-
cyte-derived macrophages within the inflamed CNS is closely related to
the axon-glial units. Indeed, monocyte-derived infiltrated macrophages
contain intracellular inclusions of myelin, suggesting a role in trig-
gering demyelination during the initial phases of EAE (Yamasaki et al.,
2014). However, there is no data about the role of monocyte-derived
macrophages at the peak of EAE, the time point studied here.
5. Conclusions
In summary, we propose here a new method to measure the disease
severity in the EAE model of MS, the so-called SI, which relates the
strongest affectation of each animal, i.e. the peak of the clinical course,
to the time elapsed from the onset of the disease symptoms. This in-
dicates that it is important to measure the severity of the clinical course
as an integrated clinical sign of the degree of affectation and the time in
which it develops. Indeed, we consider this SI as the most useful and
comprehensive parameter to be analyzed for EAE, since it is clearly
related to the peripheral immune and CNS environment found in each
animal and, last but not least, it is closer to the tools used in the clinical
practice for MS. Moreover, we show that this new SI is correlated to the
peripheral MDSC content at the peak of the EAE, whereby the more
abundant these regulatory cells, the less severe the clinical course, to-
gether with milder histopathological affectation in the inflamed CNS.
These data open the door for MDSCs to be considered as important
factors for future prospective studies establishing the relationship be-
tween these regulatory cells and the future disease severity, a research
area still to be fully explored.
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